vs
Side-by-side financial comparison of ECB Bancorp, Inc. (ECBK) and Spero Therapeutics, Inc. (SPRO). Click either name above to swap in a different company.
Spero Therapeutics, Inc. is the larger business by last-quarter revenue ($12.6M vs $9.5M, roughly 1.3× ECB Bancorp, Inc.). Spero Therapeutics, Inc. runs the higher net margin — 250.7% vs 27.3%, a 223.4% gap on every dollar of revenue. On growth, Spero Therapeutics, Inc. posted the faster year-over-year revenue change (24080.8% vs 33.8%). Over the past eight quarters, Spero Therapeutics, Inc.'s revenue compounded faster (847.7% CAGR vs 23.8%).
ECB Bancorp, Inc. (MD) is a US-based bank holding company. It offers a full suite of retail and commercial banking products including deposit accounts, consumer loans, commercial financing and wealth management solutions, primarily serving individuals and small-to-mid enterprises across local markets in Maryland.
ECBK vs SPRO — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $9.5M | $12.6M |
| Net Profit | $2.6M | $31.5M |
| Gross Margin | — | — |
| Operating Margin | 36.7% | — |
| Net Margin | 27.3% | 250.7% |
| Revenue YoY | 33.8% | 24080.8% |
| Net Profit YoY | 79.5% | 250.9% |
| EPS (diluted) | $0.32 | $0.56 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $9.5M | $12.6M | ||
| Q3 25 | $8.8M | $0 | ||
| Q2 25 | $8.0M | $0 | ||
| Q1 25 | $6.9M | $12.0K | ||
| Q4 24 | $7.1M | $52.0K | ||
| Q3 24 | $6.6M | $65.0K | ||
| Q2 24 | $6.3M | $114.0K | ||
| Q1 24 | $6.2M | $140.0K |
| Q4 25 | $2.6M | $31.5M | ||
| Q3 25 | $2.4M | $-7.4M | ||
| Q2 25 | $1.4M | $-1.7M | ||
| Q1 25 | $1.3M | $-13.9M | ||
| Q4 24 | $1.4M | — | ||
| Q3 24 | $1.1M | $-17.1M | ||
| Q2 24 | $791.0K | $-17.9M | ||
| Q1 24 | $621.0K | $-12.7M |
| Q4 25 | 36.7% | — | ||
| Q3 25 | 37.0% | — | ||
| Q2 25 | 23.9% | — | ||
| Q1 25 | 24.9% | -122758.3% | ||
| Q4 24 | 27.3% | — | ||
| Q3 24 | 23.3% | -28604.6% | ||
| Q2 24 | 16.9% | -16720.2% | ||
| Q1 24 | 13.4% | -9987.1% |
| Q4 25 | 27.3% | 250.7% | ||
| Q3 25 | 27.7% | — | ||
| Q2 25 | 18.0% | — | ||
| Q1 25 | 18.7% | -115550.0% | ||
| Q4 24 | 20.3% | — | ||
| Q3 24 | 17.2% | -26380.0% | ||
| Q2 24 | 12.6% | -15668.4% | ||
| Q1 24 | 10.0% | -9049.3% |
| Q4 25 | $0.32 | $0.56 | ||
| Q3 25 | $0.29 | $-0.13 | ||
| Q2 25 | $0.17 | $-0.03 | ||
| Q1 25 | $0.16 | $-0.25 | ||
| Q4 24 | $0.18 | — | ||
| Q3 24 | $0.14 | $-0.32 | ||
| Q2 24 | $0.09 | $-0.33 | ||
| Q1 24 | $0.07 | $-0.24 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $82.8M | $40.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $171.9M | $59.0M |
| Total Assets | $1.6B | $68.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $82.8M | $40.3M | ||
| Q3 25 | $201.9M | $48.6M | ||
| Q2 25 | $191.0M | $31.2M | ||
| Q1 25 | $143.7M | $48.9M | ||
| Q4 24 | $309.4M | $52.9M | ||
| Q3 24 | $114.8M | $76.3M | ||
| Q2 24 | $108.7M | $63.5M | ||
| Q1 24 | $109.8M | $82.3M |
| Q4 25 | $171.9M | $59.0M | ||
| Q3 25 | $169.3M | $26.5M | ||
| Q2 25 | $168.3M | $32.8M | ||
| Q1 25 | $168.6M | $33.8M | ||
| Q4 24 | $168.3M | $46.1M | ||
| Q3 24 | $166.0M | $65.5M | ||
| Q2 24 | $166.5M | $80.5M | ||
| Q1 24 | $165.8M | $96.2M |
| Q4 25 | $1.6B | $68.9M | ||
| Q3 25 | $1.6B | $54.2M | ||
| Q2 25 | $1.5B | $62.1M | ||
| Q1 25 | $1.5B | $77.7M | ||
| Q4 24 | $1.4B | $110.5M | ||
| Q3 24 | $1.4B | $135.2M | ||
| Q2 24 | $1.3B | $149.9M | ||
| Q1 24 | $1.3B | $167.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $9.2M | $-8.4M |
| Free Cash FlowOCF − Capex | $9.0M | — |
| FCF MarginFCF / Revenue | 94.7% | — |
| Capex IntensityCapex / Revenue | 2.2% | — |
| Cash ConversionOCF / Net Profit | 3.55× | -0.26× |
| TTM Free Cash FlowTrailing 4 quarters | $14.2M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $9.2M | $-8.4M | ||
| Q3 25 | $4.0M | $17.4M | ||
| Q2 25 | $1.9M | $-17.7M | ||
| Q1 25 | $-631.0K | $-4.0M | ||
| Q4 24 | $6.2M | $-23.4M | ||
| Q3 24 | $861.0K | $12.8M | ||
| Q2 24 | $1.4M | $-18.7M | ||
| Q1 24 | $-429.0K | $5.9M |
| Q4 25 | $9.0M | — | ||
| Q3 25 | $4.0M | — | ||
| Q2 25 | $1.8M | — | ||
| Q1 25 | $-649.0K | — | ||
| Q4 24 | $6.2M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $1.3M | — | ||
| Q1 24 | $-449.0K | — |
| Q4 25 | 94.7% | — | ||
| Q3 25 | 44.9% | — | ||
| Q2 25 | 23.0% | — | ||
| Q1 25 | -9.4% | — | ||
| Q4 24 | 86.8% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 21.4% | — | ||
| Q1 24 | -7.2% | — |
| Q4 25 | 2.2% | — | ||
| Q3 25 | 0.8% | — | ||
| Q2 25 | 0.6% | — | ||
| Q1 25 | 0.3% | — | ||
| Q4 24 | 0.8% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.6% | — | ||
| Q1 24 | 0.3% | — |
| Q4 25 | 3.55× | -0.26× | ||
| Q3 25 | 1.65× | — | ||
| Q2 25 | 1.32× | — | ||
| Q1 25 | -0.49× | — | ||
| Q4 24 | 4.31× | — | ||
| Q3 24 | 0.76× | — | ||
| Q2 24 | 1.75× | — | ||
| Q1 24 | -0.69× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
